Summary of clinical trials using therapies based on DCs
| Method used for tolDCs generation | Clinical trial phase | Target disease | Results | References |
|---|---|---|---|---|
| ATDCs treated with Dexa | Phase 1 | RA | Synovitis decreased Safe and well-tolerated | [78] |
| Semi-mature DCs treated with Dexa and vitA | Phase 1 | Crohn’s disease | Clinical improvement in 1/3 of patients Well-tolerate | [79] |
| ATDCs treated with vitD3 and pulsed with proinsulin peptide (C19-A3) | Phase 1 | T1D | Safe No systemic immunosuppression | [81] |
| DCs treated with Dexa and vitD3 and pulsed with auto-Ags collected from inflamed synovial joints | Phase 1 | RA | Clinical improvement No side effects No systemic immunomodulatory effect | [82] |
| Semi-mature ATDCs pulsed with 4 Ags related to RA | Phase 1 | RA | Good to moderate EULAR score Minimal side effects | [84] |
| DCs generated in the presence of NF-kB inhibitor and pulsed with RA Ags | Phase 1 | RA | Decreased DAS-28 score | [85] |
This table presents the various clinical trials using tolDCs to target autoimmune and inflammatory diseases. ATDCs: autologous tolDCs; EULAR: European Alliance of Associations for Rheumatology; DAS-28: disease activity score 28; Dexa: dexamethasone; vitA: vitamin A